The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi™) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the “Meeting”), to be held on Tuesday, 10 May 2022 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
Due to the coronavirus, the Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting in accordance with the regulations in Sobi’s Articles of Association.
Right to participate and registration
Participation at the meeting venue
(A) A person who wishes to attend the meeting venue in person or by proxy must
If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder shall be issued for the proxy. Proxy forms are available at the company’s website www.sobi.com. If the power of attorney has been issued by a legal entity, a registration certificate or corresponding authorisation must be enclosed. In order to facilitate registration at the Meeting, the power of attorney, registration certificate and other authorisation documents should be received by the company at the address stated above no later than 9 May 2022.
Participation by postal voting
(B) A person who wishes to participate in the Annual General Meeting by postal voting must
A person who wishes to attend the meeting venue in person or by proxy must give notice in accordance with (A) above. Hence, a notice of participation only through postal voting is not sufficient for a person who wishes to attend the meeting venue.
A special form shall be used for postal voting. The postal voting form is available at the company’s website www.sobi.com.
The completed and signed postal voting form may be sent by mail to Swedish Orphan Biovitrum AB (publ), “Annual General Meeting”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden or by email to [email protected]. The completed form must be received by Euroclear Sweden AB no later than 4 May 2022. Shareholders may also submit their postal votes electronically through verification with BankID via Euroclear Sweden AB’s website https://anmalan.vpc.se/euroclearproxy?sprak=1. Such electronic votes must be submitted no later than 4 May 2022.
The shareholder may not provide specific instructions or conditions to the postal voting form. If so, the vote (i.e. the postal vote in its entirety) is invalid. Further instructions and conditions are included in the postal voting form and at https://anmalan.vpc.se/euroclearproxy?sprak=1.
If the shareholder submit its postal vote by proxy, a written and dated power of attorney signed by the shareholder shall be enclosed with the postal voting form. Proxy forms are available at the company’s website www.sobi.com. If the shareholder is a legal entity, a registration certificate or corresponding authorisation must be enclosed with the form.
Nominee registered shares
In order to be entitled to participate in the Meeting, a shareholder whose shares are registered in the name of a nominee must, in addition to giving notice of participation, register its shares in its own name so that the shareholder is listed in the presentation of the share register as of 2 May 2022. Such re-registration may be temporary (so-called voting rights registration), and request for such voting rights registration shall be made to the nominee, in accordance with the nominee’s routines, at such a time in advance as decided by the nominee. Voting rights registrations that have been made by the nominee no later than 4 May 2022 will be taken into account in the presentation of the share register.
Proposed agenda
________________________
Election of the chairman of the Meeting (item 2)
The Nomination Committee of Swedish Orphan Biovitrum AB (publ), which consists of Håkan Björklund (chairman of the Board of Directors), Petra Hedengran, chairman (Investor AB), Lennart Francke (Swedbank Robur Fonder AB) and Thomas Ehlin (The Fourth Swedish National Pension Fund (AP4)), proposes that attorney-at-law Eva Hägg from Mannheimer Swartling Advokatbyrå is elected chairman of the Meeting.
Appropriation of the company’s profit or loss in accordance with the adopted balance sheet (item 11)
The Board of Directors proposes no dividend and that the company’s retained profits are carried forward.
Fees for the members of the Board of Directors and the auditor (item 13)
The Nomination Committee proposes the following:
The number of members of the Board of Directors, deputy directors, auditors and deputy auditors (item 14)
The Nomination Committee proposes the following:
Election of the chairman, the members of the Board of Directors and the auditor (item 15)
The Nomination Committee proposes the following:
Bo Jesper Hansen
Bo Jesper Hansen (born 1958) has a MD-PhD from the University of Copenhagen.
Bo Jesper is a member of the Board of Directors of Reapplix A/S, Laborie Inc. and Orphazyme A/S. He is also Senior Advisor at EQT and Global Healthcare Advisor at Goldman Sachs, as well as Venture partner at Wellington Partners, Senior Business Advisor at HBM Ventures and Advisor at Aescap Venture Fund. He has a long history within the Sobi group and, among other things, established Orphan Denmark A/S and Orphan Norway AS. Bo Jesper was also CEO of Swedish Orphan International AB 1998–2010, co-founder of Swedish Orphan Biovitrum AB (publ) and executive chairman of the Board of Directors of Swedish Orphan Biovitrum AB (publ) 2010–2016. He has previously served on the Board of Directors of a number of listed companies and also has extensive experience from several executive positions within research and development in the international pharmaceutical industry.
The Nomination Committee recommends the elected board members to build their own holdings of shares in the company
Similar to previous years, the Nomination Committee recommends the Board of Directors of Swedish Orphan Biovitrum AB (publ) to establish a shareholding policy pursuant to which the members of the Board of Directors, who do not already have such holding, are expected to, over a five year period, acquire an ownership in Swedish Orphan Biovitrum AB (publ) shares with a market value which is expected to correspond to at least one year board remuneration, before taxes, excluding remuneration for committee work.
Approval of the remuneration report (item 16)
The Board proposes that the Meeting resolves to approve the remuneration report pursuant to Chapter 8, section 53 a of the Swedish Companies Act.
Implementation of a Management Programme and an All Employee Programme in accordance with A.I and A.II, respectively, and hedging arrangements in respect thereof in accordance with B or C (item 17)
Background
The Board of Directors of Swedish Orphan Biovitrum AB (publ) (“Sobi”) proposes that the Annual General Meeting 2022 resolves on the implementation of long-term incentive programmes, giving all permanent employees of the Sobi Group the opportunity of becoming shareholders in Sobi. A division into two parts is proposed: (I) one part directed to managers and executives (the “Management Programme”) and (II) one part directed to all other employees (the “All Employee Programme”, jointly with the Management Programme, the “Programmes”), with separate resolutions on each part.
The overall purpose of the Programmes is to closely align the employees’ interests with those of the shareholders and to create a long-term commitment to Sobi. The Management Programme provides Sobi with a crucial component of a competitive total remuneration package with which to attract and retain executives who are critical to Sobi’s long-term success. The purpose of the All Employee Programme is to create commitment and motivation for the entire permanent workforce of the Sobi Group. For these reasons the Board of Directors considers that having recurring long-term incentive programmes is a vital and important part of Sobi’s total remuneration package.
The Board of Directors of Sobi has evaluated the long-term incentive programmes approved by the Annual General Meeting 2021 and has concluded that the All Employee Programme as well as the Management Programme work well and satisfy the intended purposes.
Similar to the incentive programme approved by the Annual General Meeting 2021, the Programme shall be inspiring, achievable, easy to understand, cost effective to administer, easy to communicate and in line with market practice. Following implementation of the Programme, the Board of Directors intends to carry out an evaluation thereof in order to systematically analyse the achieved results in relation to the aims outlined above. The aim of the evaluation will be to determine whether the Programme satisfies its purposes, and this will also include a review of the outcome and the costs for the Programme.
The Board of Directors proposes that the Annual General Meeting 2022 resolves on implementation of the Programmes in accordance with the principal terms and conditions set out below:
It is proposed that the Management Programme be open to no more than 336 permanent employees of the Sobi Group, whereof no more than 270 employees on director level of the Sobi Group (“Band D”), no more than 35 employees on vice president level of the Sobi Group (“Band C”), no more than 15 pre-selected key employees of the Sobi Group (“Band B2”), no more than 15 employees who are members of the Executive Committee of the Sobi Group (“Band B1”) and the CEO of Sobi (“CEO”), on the following terms and conditions and the terms and conditions set out in item A.III below.
Performance shares
Absolute TSR1 increase
60% of an LTIP Award granted to a participant will be subject to satisfaction of certain levels of absolute TSR increase over the Vesting Period. In order for any vesting related to absolute TSR increase to occur, the TSR must increase by more than 10% over the Vesting Period. In order for full vesting related to absolute TSR increase to occur, the TSR must increase by at least 40% over the Vesting Period. If the TSR increase is between 10% and 40% over the Vesting Period, a linear vesting related to absolute TSR increase will occur. The calculation of the TSR shall for the purpose of the TSR performance condition be based on a comparison of the volume-weighted average price paid for the Sobi common share on Nasdaq Stockholm, adjusted for any dividend payments, during a period of ten trading days in connection with the start of the Vesting Period and the volume-weighted average price paid for the Sobi common share on Nasdaq Stockholm, adjusted for any dividend payments, during the last ten trading days of the Vesting Period.
Annual revenues
40% of an LTIP Award granted to a participant will be subject to the Sobi Group’s actual annual revenues reaching or exceeding the Sobi Group’s target annual revenues, as set out in the budget established by the Board of Directors. A comparison shall be made for each of the financial years 2022, 2023 and 2024. If the threshold is reached or exceeded for a financial year, full vesting related to annual revenues in respect of that financial year will occur (i.e. 1/3 of 40%). If the threshold is not reached for a financial year, no vesting related to annual revenues in respect of that financial year will occur.
Employee stock options
CEO: no more than 348,730 Options.
Band B1: no more than between 41,962 and 115,635 Options per person, depending on the size of the gross annual fixed salary in 2022.
Band B2: no more than between 22,873 and 77,575 Options per person, depending on the size of the gross annual fixed salary in 2022.
It is proposed that the All Employee Programme be open to approximately 840 permanent employees of the Sobi Group (“Employees”), on the following terms and conditions and the terms and conditions set out in item A.III below.
________________________
Costs for the Programmes etc.
The costs for the Programmes, which are charged in the profit and loss account, are calculated according to the accounting standard IFRS 2 and distributed on a linear basis over the Vesting Period. The calculation has been made based on the following assumptions: (i) a market price of the Sobi common share of SEK 186, (ii) no dividend is paid by Sobi during the Programmes, (iii) an assessment of future volatility in respect of the Sobi common share, (iv) full vesting of Management Performance Shares related to annual revenues will occur, and (v) full vesting of Options. In total, this can lead to maximum costs for the Programmes of approximately SEK 248.7 million, excluding social security costs. The costs for social security charges are calculated to approximately SEK 115.7 million assuming an annual share price increase of 10% during the Vesting Period. In addition to what is set forth above, the maximum costs for the Programmes have been based on a share price of SEK 186 at the time of the commencement of the Vesting Period, that the Programmes comprise 1,176 participants in total, that each All Employee Programme participant makes a maximum investment and based on historical employee turnover for the Sobi Group of 10%. If the share price increases from SEK 186 with 10% until the implementation of the Programmes the effect on costs would only be marginal as the number of Employee Matching Shares, Management Performance Shares and Option Shares would be reduced correspondingly. Also in case of a decrease in the share price the effect on costs would be marginal. Based on the assumptions above the annual costs for the Programmes, including social security charges, corresponds to approximately 4.0% of Sobi’s total annual employee costs.
If the Programmes had been implemented in 2021, if the company had had costs in accordance with the example in the preceding paragraph, and Employee Matching Shares, Management Performance Shares and Option Shares had been allocated in 2021 in accordance with the assumptions in the sample calculation, which among other things assumes an annual share price increase of 10% during the Vesting Period, the earnings per share for the financial year 2021 had decreased by SEK 0.47 to SEK 8.61 and the shareholders’ equity per share for the financial year 2021 had decreased by SEK 1.34 to SEK 74.26.
Dilution
Upon full allocation of Employee Matching Shares, Management Performance Shares and Option Shares, the number of shares under the Programmes amounts to 3,912,968 common shares in Sobi, corresponding to a dilution effect of approximately 1.31% of the share capital and the votes. Aggregated with the 1,002,566 shares that may be transferred in order to cover the cash flow effects associated with the Programmes, primarily social security charges, the maximum dilution effect of the Programmes amounts to approximately 1.64% of the share capital and the votes. If all outstanding long-term incentive programmes are included in the calculation, then the corresponding maximum level of dilution amounts to 2.86%.
Hedging arrangements
The Board of Directors has considered different methods for transfer of shares under the Programmes, in order to implement the Programmes in a cost-effective and flexible manner. The Board of Directors has found the most cost-effective alternative to be, and thus proposes that the Annual General Meeting as a main alternative resolves on (i) a directed issue of redeemable and convertible series C shares and (ii) an authorisation for the Board of Directors to resolve on the repurchase of all issued redeemable and convertible series C shares. Following conversion to common shares in Sobi, the shares are intended to be transferred to the participants of the Programmes as well as transferred on a regulated market in order to cover the cash flow effects associated with the Programmes, primarily social security charges. For this purpose, the Board of Directors further proposes that the Annual General Meeting resolves (iii) on transfers of own common shares free of charge to the participants of the Programmes. As further described in item B.III below, the Board of Directors proposes that shares acquired for the purpose of securing Sobi’s obligations under previous incentive programmes also may be transferred under the Programmes. The detailed conditions for the Board of Directors’ main alternative are set out in item B. below.
Since the Programmes, in principle, are not expected to give rise to any initial social security payments for the Sobi Group, the Board of Directors has decided not to propose to the Annual General Meeting 2022 to resolve on transfers of own common shares on a regulated market in order to cover such payments. However, prior to the transfers of common shares to the participants of the Programmes, the Board of Directors intends to propose to the Annual General Meeting 2024 that transfers be made of own common shares on a regulated market in order to cover such costs.
Should the majority required under item B. below not be reached, the Board of Directors proposes that Sobi shall be able to enter into an equity swap agreement with a third party, in accordance with item C. below.
Preparations of the proposal
The Compensation & Benefits Committee of Sobi has prepared guidelines for the proposed Programmes. These guidelines have been presented for and adopted by the Board of Directors.
The Board of Directors has established shareholding guidelines which recommend that the CEO and other members of the Executive Committee (Band B1 participants) accumulate personal holdings in Sobi shares representing a value of an annual gross base salary for the CEO and 50% of an annual gross base salary for other members of the Executive Committee, by maintaining Sobi shares already held as well as Sobi shares allocated under the Programmes and under previous incentive programmes. It is recommended that the personal holding of shares is established within three years from being appointed Executive Committee Member. It is recommended that the CEO and other Executive Committee members maintain shares of such a value for the duration of their appointment as CEO or other Executive Committee member.
________________________
Hedging arrangements in respect of the Programmes
Increase of Sobi’s share capital by no more than SEK 1,476,175.17 through an issue of no more than 2,690,287 series C shares in Sobi. The issue shall be effected on the following terms:
Authorisation for the Board of Directors to decide on a repurchase of all issued redeemable and convertible series C shares in Sobi on the following terms:
The repurchase of own shares is an integrated part of the hedging arrangements for the Programmes. The reason for the proposed possibility to repurchase own shares is that Sobi shall be able to fulfil its obligations pursuant to the Programmes in a cost-effective manner.
Series C shares have been issued and repurchased by Sobi under previous incentive programmes for the purpose of securing Sobi’s obligations under such programmes. Those shares have been converted to common shares. Full allocation of shares will not take place under these programmes and, accordingly, all shares will not be required to secure the obligations under such programmes. The Board of Directors proposes that 2,225,247 common shares, which are no longer required to secure the obligations of Sobi under previous incentive programmes, together with the shares issued and repurchased in accordance with items B.I and B.II above, following conversion to common shares, may be transferred under the Programmes.
Transfers of Sobi’s own common shares to the participants of the Programmes may be made on the following terms:
Should the majority required under item B. above not be reached, the Board of Directors proposes that the Annual General Meeting resolves that the expected financial exposure of the Programmes shall be hedged by Sobi being able to enter into an equity swap agreement with a third party on terms in accordance with market practice, whereby the third party in its own name shall be entitled to acquire and transfer common shares in Sobi to participants of the Programmes.
________________________
Conditions
The Annual General Meeting’s resolution on the implementation of the Management Programme according to item A.I above and the Annual General Meeting’s resolution on the implementation of the All Employee Program according to item A.II above, respectively, are conditional upon Annual General Meeting either resolving in accordance with the Board of Directors’ proposal under item B. above or in accordance with the Board of Directors’ proposal under item C. above.
Majority requirements, etc.
Each of the Annual General Meeting’s resolutions according to item A.I and item A.II above requires a simple majority of the votes cast. A valid resolution under item B. above requires that shareholders representing not less than nine-tenths of the votes cast as well as of the shares represented at the Annual General Meeting approve the resolution. A valid resolution under item C. above requires a simple majority of the votes cast.
The issue, repurchase and transfer of shares in Sobi are integral parts of the proposed Programmes. Therefore, and in light of the above, the Board of Directors considers it to be advantageous for Sobi and the shareholders that the Programmes’ participants are invited to become shareholders in Sobi.
For the purpose of minimising Sobi’s costs for the Programmes, the subscription price has been set at the quotient value of the share.
Previous incentive programmes in Sobi
For a description of the company’s other long-term incentive programmes, reference is made to the company’s annual report for 2021, note 10, and the company’s website, www.sobi.com. No other long-term incentive programmes than those described herein or in the annual report for 2021, note 10, have been implemented in Sobi.
Authorisation for the CEO
The Board of Directors proposes that the CEO shall be authorized to make the minor adjustments to the above resolution regarding the directed issue of redeemable and convertible series C shares in connection with the registration thereof with the Swedish Companies Registration Office (Sw: Bolagsverket) and Euroclear Sweden AB.
Approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 18)
The Board of Directors proposes that the Annual General Meeting resolves to authorise the Board of Directors to resolve, on one or several occasions, prior to the next Annual General Meeting, on a pre-emptive or non-pre-emptive basis, on the issuance of shares and/or convertible bonds and/or warrants. Such resolution may provide for payment in kind, payment against set-off of claims and/or on other conditions. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants may not exceed 34,125,000 shares in total.
If the authorisation is exercised in full, the dilution would amount to approximately 10% of the number of shares in the company (counted after the authorisation has been fully exercised).
The Board of Directors, or any person appointed by it, is authorised to make any minor adjustments to the resolution that may be necessary to enable registration with the Swedish Companies Registration Office.
Majority requirements, etc.
The purpose of the authorisation is to enable payment through the issuance of own financial instruments in connection with possible transactions that the company may make as well as to raise capital in order to finance completed or future transactions that the company may make. A valid resolution in accordance with the Board of Directors’ proposal requires that shareholders representing at least two-thirds of both the number of votes cast and the shares represented at the Annual General Meeting support the resolution.
Transfer of own shares (item 19)
The Board of Directors proposes that the Annual General Meeting resolves that not more than 593,859 common shares may, prior to the Annual General Meeting 2023, be transferred for the purpose of covering certain payments, primarily social security charges that may occur in relation to the Incentive Programme 2019. Transfer of shares shall be effected on Nasdaq Stockholm at a price within the, at each time, prevailing price interval for the share. The number of shares that may be transferred shall be subject to recalculation in the event of an intervening bonus issue, split, rights issue and/or other similar events.
Majority requirements, etc.
The purpose of the Board of Directors’ proposal to transfer shares is to secure for future cash flow effects due to payments of social security costs connected with the Incentive Programme 2019. A valid resolution requires approval of shareholders representing at least two-thirds of the votes cast as well as the shares represented at the Annual General Meeting.
________________________
Shares and votes
As per the date of this notice there are 307,114,495 shares issued in the company. All shares are common shares representing one vote each. The company holds 11,959,198 own common shares, which cannot be represented at the Meeting.
Documents
Information regarding all board members proposed to the Board of Directors of Swedish Orphan Biovitrum AB (publ), the Nomination Committee’s proposal and motivated opinion as well as proxy and postal voting forms are available on the company’s website. The annual report, the audit report, the auditor’s statement pursuant to Chapter 8, Section 54 of the Swedish Companies Act regarding the remuneration guidelines for the group management, the remuneration report pursuant to Chapter 8, Section 53 a of the Swedish Companies Act, and the Board of Directors’ statement pursuant to Chapter 19, Section 22 of the Swedish Companies Act will be available at the company’s head office at Tomtebodavägen 23A, in Solna, Sweden, and at the company’s website, www.sobi.com, by Tuesday, 19 April 2022 at the latest, and will also be sent without charge to those shareholders who so request and who inform the company of their postal address. In respect of the other items, complete proposals are provided under the respective item in the notice.
Information at the Annual General Meeting
The Board of Directors and the CEO shall, if any shareholder so requests and the Board of Directors believes that it can be done without material harm to the company, provide information regarding circumstances that may affect the assessment of an item on the agenda, circumstances that can affect the assessment of the company’s or its subsidiaries’ financial situation or the company’s relation to other companies within the group. Shareholders may submit questions in advance by sending them to Swedish Orphan Biovitrum AB (publ), “Annual General Meeting”, SE-112 76 Stockholm or by email: [email protected].
Processing of personal data
For information on how personal data is processed in connection with the Annual General Meeting, visit https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
Stockholm in April 2022
Swedish Orphan Biovitrum AB (publ)
The Board of Directors
References
1. Total Shareholder Return.
2. The quotient value of the share as per the day of this notice is approximately SEK 0.55.
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.